OS-01: Side Effects & Safety

As a topical cosmetic product, OS-01 has a favorable safety profile limited by the low systemic exposure of topical application. It is regulated as a cosmetic, not a pharmaceutical, and has not undergone FDA drug approval processes.

• Mild skin irritation: Possible with any new topical product, particularly for sensitive skin
• No systemic effects reported: Topical application limits systemic exposure

Independent replication of OneSkin's published results by outside research groups is limited. Long-term effects of chronic senescent cell depletion in skin are unknown. The proprietary nature of the peptide and formulation limits independent verification. The cosmetic (not drug) regulatory pathway has lower evidence requirements than pharmaceutical approval.

• Known skin sensitivity or allergy to product ingredients
• Active skin infections or open wounds at application site
• Concurrent use of prescription retinoids (potential irritation)